PF-06424439 methanesulfonate

• CAT Number: I018508
• CAS Number: 1469284-79-4
• Molecular Formula: C23H30ClN7O4S
• Molecular Weight: 536.05
• Purity: ≥95%
• Synonyms: [(3R)-1-[2-[1-(4-chloropyrazol-1-yl)cyclopropyl]-1H-imidazo[4,5-b]pyridin-5-yl]piperidin-3-yl]-pyrrolidin-1-ylmethanone;methanesulfonic acid
• InChI: InChI=1S/C22H26ClN7O.CH4O3S/c23-16-12-24-30(14-16)22(7-8-22)21-25-17-5-6-18(26-19(17)27-21)29-11-3-4-15(13-29)20(31)28-9-1-2-10-28;1-5(2,3)4/h5-6,12,14-15H,1-4,7-11,13H2,(H,25,26,27);1H3,(H,2,3,4)/t15-;/m1./s1
• InChIKey: ZSTFDNQQOJUJFL-XFULWGLBSA-N
• SMILES: CS(=O)(=O)O.C1CCN(C1)C(=O)[C@@H]2CCCN(C2)C3=NC4=C(C=C3)NC(=N4)C5(CC5)N6C=C(C=N6)Cl

PF-06424439 methanesulfonate（Cat No.:I018508）is an orally bioavailable small-molecule inhibitor of diacylglycerol acyltransferase 2 (DGAT2), an enzyme critical for triglyceride biosynthesis in the liver. By blocking DGAT2 activity, this compound reduces hepatic triglyceride accumulation, making it a promising therapeutic candidate for nonalcoholic steatohepatitis (NASH), fatty liver disease, and related metabolic disorders. Preclinical studies have demonstrated its ability to lower liver fat content and improve metabolic parameters. The methanesulfonate salt form enhances solubility and stability, supporting its use in experimental and clinical research on lipid metabolism and liver disease treatment.